diabetesmine_logo_small
Have Type 2 Diabetes? Take This Survey
Amy Tenderich of Diabetes Mine is compiling data for an article in the ADA journal Diabetes Spectrum.  The article will discuss feedback from…
Running Again and Feeling Better
Last week, a day before my birthday (Wednesday) and exactly two weeks after my surgery, I went running for the first time. I ran one mile at a very slow…
Understanding Privilege: D-Dad Volunteers for Life for a Child
There are no funds for blood glucose meters or strips so Dr. Pendsey guesstimates insulin doses by age and weight. Preliminary results from a baseline study led by Drs. Zuijdwijk, Ahmet and Pendsey suggest suggests that average A1Cs are very high. LFAC supports about 100 of the Dream Trust’s patients, and is always trying to do more.
Lilly Diabetes Launches Glucagon Mobile App
Lilly Diabetes today announced the release of a new mobile application designed for caregivers and healthcare providers who support people with type 1 diabetes. The Lilly Glucagon Mobile App is a tool to teach how to use Glucagon for injection, through simulated practice. Glucagon, 1 mg (1 unit), is indicated to treat severe hypoglycemia (low blood sugar). Severe hypoglycemia due to insulin may result in loss of consciousness (insulin coma).
Pistachio Allergy, a New Villain Emerges
I celebrated my 43rd birthday on Thursday. There is no real significance in 43, it’s just like 42, but older.   And to be honest, I didn’t really…
FDA Approves Janssen’s NUCYNTA ER for Diabetic Peripheral Neuropathy Pain
The U.S. FDA has approved the supplemental New Drug Application (sNDA), submitted by Janssen Pharmaceuticals, for NUCYNTA ER (tapentadol) extended-release tablets. NUCYNTA ER is an oral analgesic taken twice daily, for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.
An In-Depth Look at the Faustman Lab Research – Part 2
Faustman holds that BCG vaccination's primary role in this case is to induce TNF-a expression, and that TNF-a's primary role in this case is to kill the defective autoreactive T cells after they have developed, implying that treatment with BCG will only work with patients who are already diabetic. Faustman put her theory to the test and treated three long-term diabetics with BCG to see whether it would have any effect on their disease status.